Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
Understanding your genetic context in GLP-1 and metabolic pathways can support a more informed, confident conversation with your provider about formulation choice, expected timeline to efficacy, and personalization strategies
Furthermore, the role of GLP-1R agonists in the treatment of neurodegenerative diseases such as Alzheimers disease (AD) and Parkinsons disease (PD) is being actively explored (Siddeeque et al., 2024)
Understanding variants in GLP1R, GIPR, FTO, and MC4R can support a more informed conversation with your provider about whether a lower-cost microdose protocol or a higher-potency compound better aligns with your predicted metabolic response
As a result, a meta-analysis of 13 RCTs revealed that GLP-1 RAs, including liraglutide, semaglutide, and dulaglutide, are associated with a 23% increased risk of rapid worsening of diabetic retinopathy in T2DM (OR, 1.23
US$ 23.95
US$ 24.68
US$ 25.39
US$ 25.09
